0226ECP Orna
BioCentury & Getty Images

Emerging Company Profile

Orna: turning circular RNAs into therapies

Emerging Company Profile: Orna launches with $80M to develop circular RNA therapies

Orna, seeded and incubated by MPM, launches with an $80 million series A and a platform of circular RNA therapies packaged in lipid nanoparticles for delivery to desired cells and tissues.

Feb 27, 2021 | 12:30 AM GMT

Orna emerged from stealth

Read the full 647 word article

How to gain access

Continue reading with a
two-week free trial.